Streptococcus agalactiae highly resistant to fluoroquinolones;Streptococcus agalactiae altamente resistante a fluoroquinolonas

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 24, Issue 9, 2006, Pages 562-563

  Miró, Elisenda ^a   Rebollo, Montserrat ^a   Rivera, Alba ^a,b   Álvarez, M Teresa ^a   Navarro, Ferrán ^a,b   Mirelis, Beatriz ^a,b   Coll, Pere ^a,b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Fluoroquinolones; gyrA; parC; Streptococcus agalactiae

Indexed keywords

ALANINE; LYSINE; MACROLIDE; PHENYLALANINE; PROTEIN PARC; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERINE; ANTIINFECTIVE AGENT; BACTERIAL DNA; BACTERIAL PROTEIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; DNA SEQUENCE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS INFECTION; AMINO ACID SUBSTITUTION; BODY FLUID; DRUG EFFECT; GENETICS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MISSENSE MUTATION; MULTIDRUG RESISTANCE; POINT MUTATION; SPAIN;

AMINO ACID SUBSTITUTION; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BODY FLUIDS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; POINT MUTATION; SPAIN; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 33845269563     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13093876     Document Type: Article

References (10)

1. Schuchat A. Epidemiology of group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev. 1998;11:497-513.
2. Liñares J, De la Campa AG, Pallarés R. Fluoroquinolone resistance in Streptococcus pneumoniae. N Engl J Med. 1999;341:1546-7; author reply 1547-8.
3. Davies TA, Goldschmidt R, Pfleger S, Loeloff M, Bush K, Sahm DF, et al. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother. 2003;52:168-75.
4. Richter SS, Heilmann KP, Beekmann SE, Miller NJ, Rice CL, Doern GV. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis. 2005;40:225-35.
5. Malhotra-Kumar S, Lammens C, Chapelle S, Mallentjer C, Weyler J, Goossens H. Clonal spread of fluoroquinolone non-susceptible Streptococcus pyogenes. J Antimicrob Chemother. 2005;55:320-5.
6. Kawamura Y, Fujiwara H, Mishima N, Tanaka Y, Tanimoto A, Ikawa S, et al. First Streptococcus agalactiae isolates highly resistant to quinolones, with point mutations in gyrA and parC. Antimicrob Agents Chemother. 2003;47:3605-9.
7. Wehbeh W, Rojas-Díaz R, Li X, Mariano N, Grenner L, Segal-Maurer S, et al. Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob Agents Chemother. 2005;49:2495-7.
8. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests-Eigth edition. Approved standard M2-A8: NCCLS, Wayne, Pa, USA; 2003.
9. González JJ, Andreu A, Spanish Group for the Study of Perinatal Infection from the Spanish Society for Clinical Microbiology and Infectious Diseases. Multicenter study of the mechanisms of resistance and clonal relationships of Streptococcus agalactiae isolates resistant to macrolides, lincosamides, and ketolides in Spain. Antimicrob Agents Chemother. 2005;49:2525-7.
10. Jones ME, Sahm DF, Martín N, Scheuring S, Heisig P, Thornsberry C, et al. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother. 2000;44:462-6.